SCHEMBL18212293

SCHEMBL18212293

OC(O)c1ccc(N2CCOCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
ALDH1A1 P00352 7/20 0.52
MAPT P10636 6/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
HTT P42858 2/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
CYP1A2 P05177 1/20 0.52
KDM4E B2RXH2 4/20 0.52
ALOX15 P16050 3/20 0.52
HSD17B10 Q99714 2/20 0.52
HPGD P15428 1/20 0.52
MAPK1 P28482 2/20 0.50
USP2 O75604 1/20 0.50
TP53 P04637 1/20 0.50
GSK3B P49841 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 2/20 0.46
ALOX12 P18054 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3158614 0.88 LMNA (0.52) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL8546835 0.84 ALDH1A1 (0.52) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL9093746 0.82 LMNA (0.71) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL10303085 0.81 ALDH1A1 (0.46) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL13451652 0.81 LMNA (0.60) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL18634579 0.81 ALDH1A1 (0.52) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL23053215 0.80 ALDH1A1 (0.49) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL7120656 0.80 ALDH1A1 (0.45) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL11372892 0.80 ABHD6 (0.45) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL22585545 0.80 CYP17A1 (0.49) LMNAALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED 2016-11-10 US disclosed
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160324864-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS SYK, BTK, LYN LMNA 4763/4885ALDH1A1 3552/4885MAPT 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.